| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1041142465 |
| P356 | DOI | 10.1038/GT.2014.67 |
| P698 | PubMed publication ID | 25077772 |
| P50 | author | Meng-Chi Yen | Q60679346 |
| P2093 | author name string | C-Y Wang | |
| J-Y Chang | |||
| Y-L Chen | |||
| M-D Lai | |||
| C-T Huang | |||
| W-C Chen | |||
| J-J Hung | |||
| T-Y Weng | |||
| P2860 | cites work | EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib | Q24561953 |
| Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer | Q27851410 | ||
| Cancer statistics, 2012 | Q27860574 | ||
| Targeting RAS signalling pathways in cancer therapy | Q28201363 | ||
| KRAS mutations in non-small cell lung cancer | Q28240568 | ||
| Regulation of interferon-gamma during innate and adaptive immune responses | Q28256001 | ||
| Combining Clinical, Pathological, and Demographic Factors Refines Prognosis of Lung Cancer: A Population-Based Study | Q28386520 | ||
| Lung cancer | Q29615473 | ||
| Tumors as organs: complex tissues that interface with the entire organism | Q30495528 | ||
| Sp1 expression regulates lung tumor progression. | Q30524654 | ||
| DNA vaccines: technology and application as anti-parasite and anti-microbial agents | Q33537293 | ||
| DNA vaccines: a key for inducing long-term cellular immunity | Q33970997 | ||
| Identification of Tumorigenic Cells in KrasG12D-Induced Lung Adenocarcinoma | Q63641289 | ||
| The dominant negative Ras mutant, N17Ras, can inhibit signaling independently of blocking Ras activation | Q73561161 | ||
| Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation | Q73734358 | ||
| Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo | Q73791493 | ||
| Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer | Q74611887 | ||
| Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device | Q78100556 | ||
| HLA-A3 restricted mutant ras specific cytotoxic T-lymphocytes induced by vaccination with T-helper epitopes | Q78837049 | ||
| Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu | Q80417682 | ||
| Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers | Q80765497 | ||
| Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome | Q81897940 | ||
| K-ras mutations in non-small-cell lung carcinoma: a review | Q33997955 | ||
| Progression to Malignancy in the Polyoma Middle T Oncoprotein Mouse Breast Cancer Model Provides a Reliable Model for Human Diseases | Q34272277 | ||
| Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies | Q34293555 | ||
| Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 | ||
| Xenogeneic Human p53 DNA Vaccination by Electroporation Breaks Immune Tolerance to Control Murine Tumors Expressing Mouse p53 | Q34607207 | ||
| Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors | Q34666826 | ||
| Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy | Q34701196 | ||
| Farnesyltransferase inhibitors: promises and realities | Q34750418 | ||
| Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins | Q35108258 | ||
| Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy | Q35917802 | ||
| DNA vaccination in the skin using microneedles improves protection against influenza | Q36085414 | ||
| Vaccination for treatment and prevention of cancer in animal models. | Q36490759 | ||
| DNA vaccines: precision tools for activating effective immunity against cancer. | Q37064852 | ||
| The effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model | Q37103859 | ||
| The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods | Q37464882 | ||
| Direct T cell activation via CD40 ligand generates high avidity CD8+ T cells capable of breaking immunological tolerance for the control of tumors | Q37659577 | ||
| Prognostic and predictive value of K-RAS mutations in non-small cell lung cancer | Q38019976 | ||
| KRAS Mutation: Should We Test for It, and Does It Matter? | Q38080822 | ||
| KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q38432430 | ||
| Global estimates of cancer prevalence for 27 sites in the adult population in 2008. | Q38920305 | ||
| Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer. | Q39478032 | ||
| GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition | Q39606314 | ||
| Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. | Q39850362 | ||
| AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl | Q40093939 | ||
| Credentialing preclinical pediatric xenograft models using gene expression and tissue microarray analysis | Q40185427 | ||
| Autologous neu DNA vaccine can be as effective as xenogenic neu DNA vaccine by altering administration route | Q40233983 | ||
| Prognostic factors in NSCLC. Recent experiences | Q40408769 | ||
| DNA immunization via intramuscular and intradermal routes using a gene gun provides different magnitudes and durations on immune response | Q40595243 | ||
| IFN-gamma induces IL-12 mRNA expression by a murine macrophage cell line, J774. | Q41487690 | ||
| The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer | Q42274351 | ||
| Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe | Q43697584 | ||
| Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer | Q44425380 | ||
| CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination | Q45864088 | ||
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 | ||
| Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. | Q46941018 | ||
| Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer | Q47862682 | ||
| The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer | Q50864449 | ||
| Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients | Q53060653 | ||
| Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial | Q53773145 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 888-896 | |
| P577 | publication date | 2014-07-31 | |
| P1433 | published in | Gene Therapy | Q15763095 |
| P1476 | title | DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model | |
| P478 | volume | 21 |
| Q92783310 | ADAM17: An Emerging Therapeutic Target for Lung Cancer |
| Q55079595 | Homoharringtonine induced immune alteration for an Efficient Anti-tumor Response in Mouse Models of Non-small Cell Lung Adenocarcinoma Expressing Kras Mutation. |
| Q99237818 | Recombinant KRAS G12D Protein Vaccines Elicit Significant Anti-Tumor Effects in Mouse CT26 Tumor Models |
| Q47137503 | Skin Delivery of Clec4a Small Hairpin RNA Elicited an Effective Antitumor Response by Enhancing CD8+ Immunity In Vivo. |
Search more.